Akero Therapeutics

South San Francisco, United Stateswww.akerotx.com1expert edge

Clinical-stage biopharmaceutical company developing novel FGF21 analogue therapies for metabolic dysfunction-associated steatohepatitis (MASH) and related metabolic diseases.

Why interesting to a deal team

Regulatory counsel on $5.2B Novo Nordisk acquisition demonstrates complex late-stage pharma M&A expertise. Valuable for assessing MASH market dynamics and clinical development strategy.

Experts connected to this company

William S. RichmondAdvised company as regulatory counsel on Novo Nordisk sale

William S. Richmond

Partner

Kirkland & Ellis LLP

LawyerWashington

Kirkland healthcare regulatory partner behind Avidity/Novartis, Akero/Novo Nordisk, Amicus/BioMarin and Curewell's CDMO investment — a direct line into live pharma services deal flow.

Sources

Page titlePrimary
akerotx.com
No name matchOther
finance.yahoo.com/quote/AKRO/profile

Strongest evidencePage title2 public sourcesHow the grades work